January 30, 2023

MultiplexDX joined the leading health tech expo in the Middle East, Arab Health 2023

18 innovative companies funded by the European Innovation Council and SMEs Executive Agency (EISMEA) successfully joined the European Pavilion at the 47th edition of the Arab Health Exhibition, representing the latest technology trends in healthcare from the EU -MultiplexDX being one of them.

Arab Health 2023 brought together key stakeholders, and top healthcare professionals, aiming to help innovative companies from around the world to scale up their businesses overseas. UAE belongs to one of the most developed healthcare markets, ready to explore and adopt state-of-the-art technologies.

Intensive meetings and discussions with key players in the field helped us gain valuable feedback on our next steps, as we are finalizing the retrospective clinical validation of breast cancer, and moving to the prospective one, which will require a lot of resources.

For more info, go to Arab Health web.

About MultiplexDX

MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).

MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.

Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter

Other latest

MultiplexDX News